Floatz logo

Sonlicromanol

MELAS

Khondrion BVSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the MELAS cohort.

Asset / SponsorPhaseRating
Fluzone
Stanford University
Phase 4BB
ARG
The Hospital for Sick Children
Phase 2B
Idebenone
Michio Hirano
Phase 2B
Zagociguat
Tisento Therapeutics
Phase 2CCC
Tti-0102
Thiogenesis Therapeutics, Inc.
Phase 2CCC

View all 10 →

Same molecule, other indications

Sonlicromanol is also rated in:

Mitochondrial DNA tRNALeu(UUR) m.3243A<G MutationDormant
BB
Indicative ·
70 / 100
View asset →
mitochondrial diseaseDormant
BB
Indicative ·
70 / 100
View asset →
maternally-inherited diabetes and deafnessDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →